Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ELDN Eledon Pharmaceuticals
2.865-0.075-2.55%
Close
02/07 16:00 ET
High
3.083
Open
2.880
Turnover
14.32K
Low
2.865
Pre Close
2.940
Volume
4.88K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
LifeSci Capital Remains a Buy on Eledon Pharmaceuticals (ELDN)
FY2023 Earnings Estimate for Eledon Pharmaceuticals, Inc. Issued By SVB Leerink (NASDAQ:ELDN)
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) – Research analysts at SVB Leerink upped their FY2023 earnings per share (EPS) estimates for shares of Eledon Pharmaceuticals in a research n
SVB Leerink Comments on Eledon Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:ELDN)
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) – Research analysts at SVB Leerink issued their FY2027 earnings per share estimates for Eledon Pharmaceuticals in a report released on Tuesd
Eledon Pharmaceuticals, EGenesis Collaborate for Use of Tegoprubart
EGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
-Agreement leverages Eledon's investigational anti-CD40L antibody, tegoprubart, as part of eGenesis' immunosuppression regimen that prevents xenotransplant rejection in nonhuman primate recipients- -Establishes
Contrasting Eledon Pharmaceuticals (NASDAQ:ELDN) and Puma Biotechnology (NASDAQ:PBYI)
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) and Puma Biotechnology (NASDAQ:PBYI – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two compa
Head to Head Contrast: Eledon Pharmaceuticals (NASDAQ:ELDN) and Puma Biotechnology (NASDAQ:PBYI)
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) and Puma Biotechnology (NASDAQ:PBYI – Get Rating) are both small-cap medical companies, but which is the superior investment? We will compare the two
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersIsoPlexis (NASDAQ:ISO) shares moved upwards by 43.5% to $0.99 during Wednesday's after-market session. The market value of their outstanding shares is at $39.1 million. Phio Pharma (NASDAQ:PHIO
C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for IBox Scoring System
IRVINE, Calif., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path) announced on December 20, 2022, that its Transplant Therapeutic Consortium (TTC) received a qualification opinion for the iBox Scoring
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Sees Large Drop in Short Interest
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) was the target of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 19,90
Company Overview
More
Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people requiring an organ or cellular transplant, and for people living with autoimmune and neurodegenerative disease. The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential. The CD40L/CD40 pathway is recognized for its prominent role in immune regulation, making it a candidate for therapeutic intervention in transplant tolerance, autoimmune disease, and neuro-inflammation. The company is building upon a deep historical understanding of the CD40/CD40L pathway, as well as preclinical and Phase 1 data, to initiate up to four phase 2 clinical studies with AT-1501. Eledon Pharmaceuticals was founded on March 26, 2004 and is headquartered in Irvine, CA.
CEO： Dr. David-Alexandre C. Gros, M.D.
Market： NASDAQ
Listing Date： 09/17/2014
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet